Technology
Health
Pharmaceutical

Aileron Therapeutics

$2.09
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.11 (-5.00%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell ALRN and other stocks, options, ETFs, and crypto commission-free!

About

Aileron Therapeutics, Inc. Common Stock, also called Aileron Therapeutics, is a clinical stage biopharmaceutical company, which focuses on developing and commercializing stapled peptides. Read More Its ALRN-6924 product targets the tumor suppressor p53 for the treatment of a wide variety of cancers. It also offers the MDMX and MDM2. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky in June 2005 and is headquartered in Cambridge, MA.

Employees
Headquarters
Cambridge, Massachusetts
Founded
2005
Market Cap
32.42M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
133.93K
High Today
$2.30
Low Today
$2.02
Open Price
$2.21
Volume
157.20K
52 Week High
$9.18
52 Week Low
$0.52

Collections

Technology
Health
Pharmaceutical
Medical
Therapy
Biopharmaceutical
2017 IPO
US

News

Markets InsiderMar 12

8 Top Gainers In Healthcare Sector (ALRN, NDRA, DOVA...)

(RTTNews) - The following are some of today's top gainers in the pharma/biotech sector. 1. Aileron Therapeutics Inc. (ALRN) Aileron is a clinical-stage company developing therapies to treat cancer and other diseases. Gained 51.43% to close Tuesday's (Mar.12) trading at $2.12. News: No news Clinical Trials & Near-term Catalysts: -- A phase IIa expansion of ALRN-6924 as monotherapy in cohorts of patients with relapsed or refractory peripheral T-cell lymphoma is underway. Interim data reported last Decem...

303
Simply Wall StMar 8

What Type Of Shareholder Owns Aileron Therapeutics, Inc.’s (NASDAQ:ALRN)?

If you want to know who really controls Aileron Therapeutics, Inc. (NASDAQ:ALRN), then you’ll have to look at the makeup of its share registry. Institutions often own shares in more established companies, while it’s not unusual to see insiders own a fair bit of smaller companies. Warren Buffett said that he likes ‘a business with enduring competitive advantages that is run by able and owner-oriented people’. So it’s nice to see some insider ownership, because it may suggest that management is owner-oriented...

148
MarketBeatFeb 23

Stock Price, News, & Analysis for Aileron Therapeutics

Aileron Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing a novel class of therapeutics in the United States. The company's lead product candidate is ALRN-6924, a stapled peptide, which is in Phase I clinical trial for the treatment of advanced solid tumors or lymphomas; Phase IIa clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); and ...

11

Earnings

-$0.56
-$0.49
-$0.42
-$0.35
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
Actual
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.